NICRN Diabetes Team achieve FPFV within 30-days to The Prospective Study

November 12, 2026

How did this event all come about?

The Northern Ireland Clinical Research Network (NICRN) & The Belfast Trust have successfully recruited its first participant within 30-days of the opening of its new clinical trial, ‘Prospective Study of the Psychiatric Side Effects of Cabergoline in the Treatment of Prolactinomas‘ in collaboration with Imperial College London Endocrine Department.

This multicentre prospective cohort study is investigating the frequency of psychiatric side effects (including changes in impulsivity, behaviour and mood disorders) associated with cabergoline treatment of prolactinomas. The study will also review the time course and explore any risk factors for the development of these side effects.

What ended up happening and who all was involved?

The successful delivery of the trial is conducted by the dedicated efforts of our research team comprised of:

Consultants Dr Philip Johnston (Principal Investigator (PI)) and Dr Ian Wallace (Sub-PI) and Dr Ben Loughrey, Regional Centre for Endocrinology & Diabetes Royal Victoria Hospital, BHSCT. NICRN would like to express its appreciation to them for the rapid identification of eligible participants with this condition, facilitating efficient study recruitment.

NICRN Diabetes Research Nurses Deslyn and Priya, who play an instrumental role in the trial’s day-to-day operation.

Special thanks

NICRN would like to extend its sincere thanks to all staff whose professionalism, dedication and collaborative efforts have contributed to this significant achievement, in addition to colleagues in the Regional Centre for Endocrinology and Diabetes, Belfast Trust for supporting the study. The team looks forward to building on this success through continued recruitment as the study progresses. The ongoing success of the trial remains dependent upon our participants, whose engagement and participation are integral to its continued advancement.